Early trials show reduction in liver fibrosis

The American Association for the Study of Liver Diseases published findings that the ASK1 Inhibitor Selonsertib reduced liver fibrosis in stage 2-3 liver fibrosis. In late 2016 Gilead announced that Selonsertib was being tested with “GS-9674″ an FXR agonist for PBC. ┬áRead more click here.